The trajectory of companies tied to the drug's history presents a challenging investment scenario . While the initial boom generated substantial gains, generic copies have significantly eroded revenue. Investing in related pharmaceutical companies now requires a discerning assessment of proprietary safeguards, evolving medical trends , and the poss